Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K.

J Transl Med. 2010 Aug 20;8:78. doi: 10.1186/1479-5876-8-78.

2.
3.

Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.

Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, Gajda M, Mosig AS, Sonnemann J, Peters S, Melnikova M, Thomale J, Dürst M, Runnebaum IB, Häfner N.

Int J Cancer. 2017 Oct 15;141(8):1600-1614. doi: 10.1002/ijc.30860. Epub 2017 Jul 12.

PMID:
28670762
4.

Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.

Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, Lin F, Zhang Q, Zhao H, Zheng F.

Int J Gynecol Cancer. 2013 Feb;23(2):256-63. doi: 10.1097/IGC.0b013e31827ad2b8.

PMID:
23358177
5.

MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.

Yan C, Yang F, Zhou C, Chen X, Han X, Liu X, Ma H, Zheng W.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2710-8. eCollection 2015.

6.

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A.

J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. Erratum in: J Pathol. 2014 Feb;232(3):e1.

7.

XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.

Ma JJ, Chen BL, Xin XY.

Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):222-6. doi: 10.1016/j.ejogrb.2009.06.011. Epub 2009 Sep 15.

PMID:
19758744
8.

Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.

Ma Z, Wang X, He J, Xia J, Li Y.

PLoS One. 2017 Mar 29;12(3):e0174037. doi: 10.1371/journal.pone.0174037. eCollection 2017.

9.

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K.

J Transl Med. 2011 Jul 21;9:114. doi: 10.1186/1479-5876-9-114.

10.

MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.

Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X.

Oncogene. 2014 Jan 16;33(3):378-86. doi: 10.1038/onc.2012.575. Epub 2013 Jan 14.

PMID:
23318422
11.

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.

Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P.

PLoS One. 2015 Jun 4;10(6):e0128886. doi: 10.1371/journal.pone.0128886. eCollection 2015.

12.

[Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].

Li Z, Wang Q, Zhang W, Yang Z, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2015 Nov;50(11):854-60. Chinese.

PMID:
26887775
13.

Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.

Xiao M, Cai J, Cai L, Jia J, Xie L, Zhu Y, Huang B, Jin D, Wang Z.

J Ovarian Res. 2017 Apr 4;10(1):24. doi: 10.1186/s13048-017-0321-8.

14.

HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.

Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L, Li P.

Mol Med Rep. 2015 Aug;12(2):2211-6. doi: 10.3892/mmr.2015.3562. Epub 2015 Mar 27.

PMID:
25824616
15.

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.

Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström PU.

BMC Urol. 2013 Apr 8;13:17. doi: 10.1186/1471-2490-13-17.

16.

miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.

Guo P, Xiong X, Zhang S, Peng D.

Oncol Rep. 2016 Dec;36(6):3552-3558. doi: 10.3892/or.2016.5140. Epub 2016 Oct 3.

PMID:
27748936
17.

MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.

Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y.

Drug Des Devel Ther. 2015 Sep 16;9:5225-35. doi: 10.2147/DDDT.S87526. eCollection 2015.

18.

High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells.

Volkmann J, Reuning U, Rudelius M, Häfner N, Schuster T, Becker V Ros A, Weimer J, Hilpert F, Kiechle M, Dürst M, Arnold N, Schmalfeldt B, Meindl A, Ramser J.

Int J Cancer. 2013 Jun 15;132(12):2820-32. doi: 10.1002/ijc.27975. Epub 2012 Dec 27.

19.

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D.

Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.

20.

Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.

Zhang R, Shi H, Ren F, Li X, Zhang M, Feng W, Jia Y.

Oncol Rep. 2016 Apr;35(4):2466-72. doi: 10.3892/or.2016.4585. Epub 2016 Jan 21.

PMID:
26794135

Supplemental Content

Support Center